mRNA Therapeutics Market Size, Share, Growth Analysis, By Type(Prophylactic Vaccines, Therapeutic Vaccines, Therapeutic Drugs), By Application(Rare Genetic Diseases, Oncology, Respiratory Diseases, Infectious Diseases), By Region - Industry Forecast 2024-2031

The competitive environment of the global mRNA therapeutics market is made up of several key players. There is a mix of renowned pharmaceutical companies and rising biotech startups, along with innovative research institutes. Some industry leaders in this market are Pfizer, Moderna, CureVac, Translate Bio, BioNTech, and Arcturus Therapeutics.

Moderna and Pfizer collaborated frequently with BioNTech during the COVID-19 pandemic. They developed pioneer mRNA COVID-19 vaccines, helping fight the virus globally. This development has steeled their place at the top of the market. The market’s top dogs use their extensive expertise of the mRNA technology, along with their huge production capacity, to maintain their share of the market.

Top Player’s Company Profiles

• CureVac AG (Germany)

• Roche Holding AG (Switzerland)

• Pfizer Inc. (USA)

• GlaxoSmithKline plc (United Kingdom)

• Moderna, Inc. (USA)

• Sanofi SA (France)

• BioNTech SE (Germany)

• Dynavax Technologies Corporation (USA)

• Arcturus Therapeutics Holdings Inc. (USA)

• AstraZeneca plc (United Kingdom)

• Regeneron Pharmaceuticals, Inc. (USA)

• Alnylam Pharmaceuticals, Inc. (USA)

• Gilead Sciences, Inc. (USA)

• Mylan N.V. (USA)

• Novartis AG (Switzerland)

• Modulus Therapeutics, Inc. (USA)

• Catalent, Inc. (USA)

• Translate Bio, Inc. (USA)

• Ionis Pharmaceuticals, Inc. (USA)

• Vertex Pharmaceuticals Incorporated (USA)